Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06664151 · ClinicalTrials.gov registry record · Early Phase 1
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
A Early Phase 1 study of Skin Cancer and Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06664151 is a Early Phase 1 study of Skin Cancer and Cutaneous Squamous Cell Carcinoma (CSCC) that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06664151, a Early Phase 1 study of Skin Cancer and Cutaneous Squamous Cell Carcinoma (CSCC), is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine could improve the immune system response against the cancer. The names of the study drug involved in this study is: -Fluzone Influenza vaccine (flu shot)
Conditions Studied
Interventions
- BIOLOGICAL Fluzone Trivalent
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2026-08-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06664151
The ClinicalTrials.gov registry entry for NCT06664151 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Skin Cancer appearing as the primary indexed condition, and to 1 intervention - of which Fluzone Trivalent is the first listed.
NCT06664151 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06664151 about?
NCT06664151 is a clinical study titled "A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision". This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine c...
What is the current status of trial NCT06664151?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2024-11-26. Estimated completion is 2026-08-30.
What conditions does trial NCT06664151 study?
This clinical trial studies the following conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer.
What interventions are being tested in trial NCT06664151?
The interventions under investigation include: Fluzone Trivalent (BIOLOGICAL).
Who is sponsoring clinical trial NCT06664151?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06664151 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Trial of Supplemental Vitamin A and Nicotinamide
RECRUITING · Early Phase 1
-
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
RECRUITING
-
Undergraduate Skin Cancer Prevention Trial
RECRUITING · Phase 3
Explore more on PlainTrial
Skin Cancer
All registered trials for this condition
Cutaneous Squamous Cell Carcinoma (CSCC)
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.